Siegfried Ltd, and its wholly-owned subsidiary Siegfried USA, form the Swiss-based Siegfried Group. Siegfried has manufacturing facilities in the United States (Pennsville, New Jersey) and Europe (Zofingen, Switzerland). Each of the multi-purpose cGMP facilities - production of APIs and advanced pharmaceutical-related intermediates - are supported by technologically advanced process research and development. In addition, Siegfried also develops and produces finished dosage pharmaceutical products. Siegfried employs over 800 people and has annual sales of 258 million USD. The Siegfried Group is traded at the Swiss Stock Exchange (SWX).  Siegfried concentrates on developing innovative technical solutions in order to supply the API and advanced intermediate needs of the worldwide traditional and emerging research-based pharmaceutical industry. Although there is a strong focus on Custom Manufacturing, Siegfried also devotes significant resources to provide the Generic portion of the industry with Controlled Substances and niche APIs.